Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of non-small cell lung cancer that is Stage III (T1-3, pN2, M0) NSCLC in whom neoadjuvant therapy is recommended.~* Must have had a mediastinoscopy to determine nodal status and potential resectability~* Must have enough tissue from the biopsy for tissue marker determination for correlative studies~* Negative metastatic work up (FDG PET/CT, brain CT or MRI)~* No prior thoracic radiotherapy will be permitted~* Age 18 years or greater~* ECOG performance status 0-1 (Karnofsky at least 70%)~* Normal organ and marrow function~* No known HIV infection~* Not pregnant~* Ability to understand and the willingness to sign an informed consent document~Exclusion Criteria:~* Patients requiring a pneumonectomy~* Patients who have had chemotherapy or radiation therapy within 4 weeks prior to entering the study, or who have not recovered from adverse events due to agents administered earlier.~* Prior thoracic radiation~* Treatment with any other investigational agents.~* Known metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to NFV~* Patients receiving drugs contraindicated with NFV will be excluded.~* Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study compliance.~* Pregnant or lactating women~* HIV-positive patients on combination antiretroviral therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nelfinavir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).